Bottom line
Is FHEQX a good fund? The bottom line
FHEQX is the Class A share class of Federated Hermes SDG Engagement Equity Fund, an actively managed large blend mutual fund from Federated Hermes.
Annual fees run 1.19% — about $119 a year on every $10,000 invested, more expensive than 73% of large blend funds we track.
It returned −3.8% over one year, +3.2% a year over five years (as of Dec 31, 2024, per its prospectus).
With $18.4 million in net assets and 58 holdings, its largest position is West Pharmaceutical Services Inc (3.0%) and the top 10 make up 25.9% of the portfolio.
This share class carries a front-end sales charge of up to 5.5%; a no-load class or ETF alternative can avoid it.
What to watch
- Expensive for its category (1.19%)
- 5-year return in the bottom quarter of its category
- Front-end sales load up to 5.5%
- Small fund ($18.4 million) — small funds are likelier to close
Updated Nov 19, 2026
What FHEQX invests in
The Funds investment objective is to provide long-term capital appreciation alongside positive societal impact. The objective may be changed by the Funds Board of Trustees (the Trustees) without shareholder approval.
The Fund pursues its investment objective of long-term capital appreciation alongside positive societal impact by investing, under normal circumstances, at least 80% of its net assets in equity securities. In seeking to achieve its objective, the Fund may invest its assets in companies of all capitalizations; however, the Funds investment adviser or sub-adviser (as applicable, the Adviser) anticipates that the Fund will be primarily invested in equity securities and equity-related securities (such as depositary receipts) of small- and mid-capitalization companies in both the United States and foreign markets (including emerging markets). The Fund may also invest in and gain exposure to securities of other investment companies, real estate investment trusts (REITs), and money market funds including funds advised by the Adviser or its affiliates. In managing the assets of the Fund, the…
From the fund's prospectus (filed Dec 29, 2025).
FHEQX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| FHEQX | −3.8% | +3.2% | — |
| Large Blend median | +13.8% | +9.7% | +10.9% |
Source: Fund prospectus, as of Dec 31, 2024
What FHEQX costs
On a $10,000 investment, FHEQX's 1.19% expense ratio costs about $119 a year. The prospectus estimates $2,284 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.
FHEQX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | West Pharmaceutical Services Inc WST | 3.04% |
| 2 | Wintrust Financial Corp WTFC | 3.00% |
| 3 | Steris Plc STE | 2.63% |
| 4 | Credicorp Ltd BAP | 2.62% |
| 5 | Viscofan Industria Navarra De Envoltura Celulosicas Sa VIS | 2.58% |
| 6 | Crane Company CR | 2.51% |
| 7 | Aptargroup Inc ATR | 2.48% |
| 8 | Reinsurance Group Of America Inc RGA | 2.46% |
| 9 | Ansell Ltd ANN | 2.35% |
| 10 | Horiba Ltd 6856 | 2.24% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 25.9% of the fund. See all top 25 holdings and asset mix →